Experimental virus injection targets Hard-to-Treat cancers in new trial
NCT ID NCT04370587
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new treatment called T3011, a modified virus injected directly into tumors, for people with advanced solid cancers like melanoma, lung cancer, or sarcoma. The study will also test T3011 combined with the immunotherapy drug pembrolizumab (Keytruda). About 30 participants will receive the treatment to check its safety and see if it shrinks tumors. The goal is to find a dose that is safe and potentially effective for further testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
T3011 (a modified virus injected into tumors) and pembrolizumab (an immunotherapy drug given intravenously)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early-phase trial with only 30 participants, so safety and effectiveness are not yet proven. The virus injection may cause side effects like inflammation or flu-like symptoms, and the combination with pembrolizumab could increase immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Banner MD Anderson Cancer Center
COMPLETEDGilbert, Arizona, 85234, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Email: •••••@•••••
Contact
-
Mary Crowley Cancer Research
RECRUITINGDallas, Texas, 75230, United States
Contact Email: •••••@•••••
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Email: •••••@•••••
Contact
-
Peninsula & South Eastern Haematology and Oncology Group
RECRUITINGFrankston, Australia
Contact Email: •••••@•••••
Contact
-
Southern Oncology
RECRUITINGBedford Park, Australia
Contact Email: •••••@•••••
Contact
-
The Alfred
RECRUITINGMelbourne, Australia
Contact Email: •••••@•••••
Contact
-
University of Pittsburgh Medical Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Email: •••••@•••••
Contact
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
Contact Email: •••••@•••••